Q3 FY2026 · ended Sep 30, 2026 · Revenue $57.71M, +0.5% YoY · Filed Nov 2, 2026
Cerus Corp (CERS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $57.7 million and a net loss of $550,000. Free cash flow was $2.4 million. As of Sep 30, 2026 it held $57.1 million in cash and investments and $11.6 million in total debt.
Revenue
$57.71M
+0.5% vs prior quarter
Net income
$-550,000
-2794.7% vs year-ago quarter
Operating cash flow
$3.01M
+56.0% vs year-ago quarter
Free cash flow
$2.42M
+2471.3% vs year-ago quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
201.95M
+5.1% vs year-ago quarter
Net cash
$45.50M
Q3 FY2026
Operating margin
0.7%
Q3 FY2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CERS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Concord, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1020214
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $57.7M | $57.4M | $53.7M | — | — |
| Operating income | $383,000 | -$1.9M | -$354,000 | -$641,000 | $1.2M |
| Net income | -$550,000 | -$2.9M | -$1.6M | -$2.2M | -$19,000 |
| Diluted EPS | $0.00 | -$0.01 | -$0.01 | -$0.01 | $0.00 |
| Operating cash flow | $3.0M | -$2.7M | -$3.0M | $6.2M | $1.9M |
| Free cash flow | $2.4M | -$3.5M | -$3.3M | $4.9M | $94,000 |
| Total assets | $204.7M | $205.2M | $222.9M | $221.9M | $215.2M |
| Total liabilities | $128.4M | $134.5M | $154.6M | $156.9M | $153.0M |
| Stockholders' equity | $75.7M | $70.0M | $67.6M | $64.2M | $61.5M |
| Cash and investments | $57.1M | $56.3M | $80.4M | $82.9M | $78.5M |
| Total debt | $11.6M | $11.9M | $12.5M | $13.1M | $13.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jun 8, 2026 | Jun 5, 2026 |
All 1000 Cerus Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.